MCPMF (Mochida Pharmaceutical Co) PE Ratio: 6.52 (As of Jul. 11, 2026) — 66% Below Median


MCPMF Mochida Pharmaceutical Co Ltd MCPMF
69 GF Score
Price $9.60
GF Value $11.22
! 4 Warning Signs
View Full Analysis

What is Mochida Pharmaceutical Co PE Ratio?

Mochida Pharmaceutical Co MCPMF 69 PE Ratio is 6.52 as of Jul. 11, 2026, which is 66% below its 10-year median of 19.08. GuruFocus rates MCPMF with a GF Score™ of 69/100 and a GF Value™ of $11.22. The stock has 4 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-11), Mochida Pharmaceutical Co's share price is $9.60. Mochida Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.47. Therefore, Mochida Pharmaceutical Co's PE Ratio for today is 6.52.

Good Sign:

Mochida Pharmaceutical Co Ltd stock PE Ratio (=14.15) is close to 3-year low of 14.06.

During the past 13 years, Mochida Pharmaceutical Co's highest PE Ratio was 39.87. The lowest was 11.04. And the median was 19.08.

Mochida Pharmaceutical Co's EPS (Diluted) for the three months ended in Mar. 2026 was $0.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.47.

As of today (2026-07-11), Mochida Pharmaceutical Co's share price is $9.60. Mochida Pharmaceutical Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $1.48. Therefore, Mochida Pharmaceutical Co's PE Ratio without NRI ratio for today is 6.51.

During the past 13 years, Mochida Pharmaceutical Co's highest PE Ratio without NRI was 39.63. The lowest was 10.67. And the median was 18.97.

Mochida Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2026 was $0.28. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $1.48.

During the past 12 months, Mochida Pharmaceutical Co's average EPS without NRI Growth Rate was 39.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 7.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -6.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was -2.10% per year.

During the past 13 years, Mochida Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 38.90% per year. The lowest was -18.40% per year. And the median was 2.80% per year.

Mochida Pharmaceutical Co's EPS (Basic) for the three months ended in Mar. 2026 was $0.28. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.47.

Back to Basics: PE Ratio


Mochida Pharmaceutical Co  (OTCPK:MCPMF) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Mochida Pharmaceutical Co PE Ratio Related Terms


Mochida Pharmaceutical Co PE Ratio Historical Data

* Premium members only.

The historical data trend for Mochida Pharmaceutical Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mochida Pharmaceutical Co PE Ratio Chart

Mochida Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.46 18.67 25.28 19.83 15.52

Mochida Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.83 17.45 16.76 19.51 15.52

MCPMF vs ZTS, UTHR: PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mochida Pharmaceutical Co PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Mochida Pharmaceutical Co's PE Ratio falls into.


MCPMF
69GF Score
Mochida Pharmaceutical Co Ltd MCPMF
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mochida Pharmaceutical Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Mochida Pharmaceutical Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=9.60/1.472
=6.52

Mochida Pharmaceutical Co's Share Price of today is $9.60.
Mochida Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.47.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 6.52 mean?
Mochida Pharmaceutical Co (MCPMF) has a PE Ratio of 6.52 as of Jul. 11, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Mochida Pharmaceutical Co and its competitors. This is 66% below median its historical median of 19.08. Over the past decade, Mochida Pharmaceutical Co's PE Ratio has ranged from 11.04 to 39.87.
Is Mochida Pharmaceutical Co's PE Ratio too high?
Mochida Pharmaceutical Co's current PE Ratio of 6.52 is 66% below median its 10-year median of 19.08. Over the past 10 years, this metric has ranged from a low of 11.04 to a high of 39.87. Overall, Mochida Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Mochida Pharmaceutical Co's PE Ratio compare to ZTS and UTHR?
Mochida Pharmaceutical Co's PE Ratio of 6.52 can be compared against companies in the Drug Manufacturers industry. Historically, Mochida Pharmaceutical Co's own PE Ratio has ranged from 11.04 to 39.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Drug Manufacturers company?
A good PE Ratio depends on the Drug Manufacturers industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Mochida Pharmaceutical Co and its competitors. Mochida Pharmaceutical Co's current PE Ratio is 6.52, which is 66% below median its own 10-year median of 19.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mochida Pharmaceutical Co stock overvalued right now?
Mochida Pharmaceutical Co (MCPMF) has a current PE Ratio of 6.52. The stock's GF Value™ is $11.22, compared to a current price of $9.60 — trading 14.4% below its estimated fair value. The current PE Ratio is 6.52, which is 66% below median its 10-year median of 19.08. Mochida Pharmaceutical Co's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Mochida Pharmaceutical Co (MCPMF), the current PE Ratio is 6.52 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mochida Pharmaceutical Co (MCPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued. The current stock price of $9.60 is trading 14.4% below its estimated GF Value™ of $11.22.

Key valuation signals for MCPMF:

  • PE Ratio: 6.52 (66% below median its 10-year median of 19.08)
  • GF Value™: $11.22 vs. price of $9.60 (14.4% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the MCPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mochida Pharmaceutical Co Business Description

Other Exchanges 4534:Japan
Address 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
69GF Score

Get the complete analysis for MCPMF

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.60
Price
$11.22
GF Value